These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34197574)

  • 21. Correlation of serum hepatitis B core-related antigen with hepatitis B virus total intrahepatic DNA and covalently closed circular-DNA viral load in HIV-hepatitis B coinfection.
    Dezanet LNC; Maylin S; Gabassi A; Rougier H; Miailhes P; Lascoux-Combe C; Chas J; Girard PM; Delaugerre C; Zoulim F; Lacombe K; Boyd A
    AIDS; 2020 Nov; 34(13):1943-1949. PubMed ID: 32773480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and Predictors of Liver Fibrosis in People Living with Hepatitis B in Senegal.
    Ramírez Mena A; Ngom NF; Tine J; Ndiaye K; Fortes L; Ndiaye O; Fall M; Gaye A; Ka D; Seydi M; Wandeler G; On Behalf Of The Sen-B Study Group
    Viruses; 2022 Jul; 14(8):. PubMed ID: 35893680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection.
    Chung RT; King WC; Ghany MG; Lisker-Melman M; Hinerman AS; Khalili M; Sulkowski M; Jain MK; Choi EK; Nalesnik MA; Bhan AK; Cloherty G; Wong DK; Sterling RK;
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):125-135.e8. PubMed ID: 34973459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
    Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E;
    BMC Gastroenterol; 2015 Jul; 15():79. PubMed ID: 26152237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Hepatitis B Core-Related Antigen and Antihepatitis B Core Antibody With Liver Fibrosis Evolution in Human Immunodeficiency Virus-Hepatitis B Virus Coinfected Patients During Treatment With Tenofovir.
    Cruchet R; Dezanet LNC; Maylin S; Gabassi A; Rougier H; Miailhes P; Lascoux-Combe C; Chas J; Girard PM; Delaugerre C; Lacombe K; Boyd A
    Open Forum Infect Dis; 2020 Jul; 7(7):ofaa215. PubMed ID: 33123612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
    Hafkin JS; Osborn MK; Localio AR; Amorosa VK; Kostman JR; Stern JJ; De La Torre P; Mounzer K; Frank I; Gross R; Chang KM; Lo Re V
    J Viral Hepat; 2014 Apr; 21(4):288-96. PubMed ID: 24597697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes of liver transplantation in human immunodeficiency virus/hepatitis B virus coinfected patients in China.
    Tang J; Weng R; Fang T; Zhang K; Yan X; Jin X; Xie L; Zhao D
    BMC Infect Dis; 2024 Apr; 24(1):383. PubMed ID: 38589801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
    Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
    Lacombe K; Gozlan J; Boelle PY; Serfaty L; Zoulim F; Valleron AJ; Girard PM
    AIDS; 2005 Jun; 19(9):907-15. PubMed ID: 15905671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal outcomes after up to 8 years of tenofovir exposure in HIV-HBV-coinfected patients.
    Boyd A; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Plaisier E; Lacombe K
    Antivir Ther; 2017; 22(1):31-42. PubMed ID: 27553871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies.
    Wandeler G; Mauron E; Atkinson A; Dufour JF; Kraus D; Reiss P; Peters L; Dabis F; Fehr J; Bernasconi E; van der Valk M; Smit C; Gjærde LK; Rockstroh J; Neau D; Bonnet F; Rauch A;
    J Hepatol; 2019 Aug; 71(2):274-280. PubMed ID: 30965070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.
    Hawkins C; Kang M; Bhattacharya D; Cloherty G; Kuhns M; Matining R; Thio C; Samaneka W; Chinula L; Mulinda N; Badal-Faesen S; Sugandhavesa P; Lama J; Gaseitsiwe S; Holzmayer V; Anderson M; Murphy R; Peters M
    AIDS; 2022 Jun; 36(7):975-984. PubMed ID: 35165216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B virus sequencing and liver fibrosis evaluation in HIV/HBV co-infected Nigerians.
    Grant J; Agbaji O; Kramvis A; Yousif M; Auwal M; Penugonda S; Ugoagwu P; Murphy R; Hawkins C
    Trop Med Int Health; 2017 Jun; 22(6):744-754. PubMed ID: 28376292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen.
    Aurpibul L; Kanjanavanit S; Leerapun A; Puthanakit T
    J Int Assoc Provid AIDS Care; 2019; 18():2325958218823259. PubMed ID: 30798669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B virus genotype G and liver fibrosis progression in chronic hepatitis B and human immunodeficiency virus coinfection.
    Malagnino V; Bottero J; Miailhes P; Lascoux-Combe C; Girard PM; Zoulim F; Lacombe K; Boyd A
    J Med Virol; 2019 Apr; 91(4):630-641. PubMed ID: 30431661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients.
    Coffin CS; Osiowy C; Myers RP; Gill MJ
    J Clin Virol; 2013 Jun; 57(2):103-8. PubMed ID: 23465393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
    Childs K; Joshi D; Byrne R; Bruce M; Carey I; Agarwal K; Taylor C
    AIDS; 2013 Jun; 27(9):1443-8. PubMed ID: 23435302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection.
    Tsai WC; Hsu WT; Liu WD; Sun HY; Chuang YC; Huang YS; Cheng A; Lin KY; Huang YC; Chen GJ; Huang SH; Sheng WH; Hsieh SM; Hung CC; Chang SC
    Liver Int; 2019 Aug; 39(8):1408-1417. PubMed ID: 30712284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.
    Idoko J; Meloni S; Muazu M; Nimzing L; Badung B; Hawkins C; Sankalé JL; Ekong E; Murphy R; Kanki P; Thio CL
    Clin Infect Dis; 2009 Oct; 49(8):1268-73. PubMed ID: 19772386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.